nach oben

Clinical and Experimental Medicine

Erschienen in:

27.07.2017 | Review Article

DNA methylation profiles in cancer diagnosis and therapeutics

verfasst von: Yunbao Pan, Guohong Liu, Fuling Zhou, Bojin Su, Yirong Li

Erschienen in: Clinical and Experimental Medicine | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Cancer initiation and proliferation is regulated by both epigenetic and genetic events with epigenetic modifications being increasingly identified as important targets for cancer research. DNA methylation catalyzed by DNA methyltransferases (DNMTs) is one of the essential epigenetic mechanisms that control cell proliferation, apoptosis, differentiation, cell cycle, and transformation in eukaryotes. Recent progress in epigenetics revealed a deeper understanding of the mechanisms of tumorigenesis and provided biomarkers for early detection, diagnosis, and prognosis in cancer patients. Although DNA methylation biomarker possesses potential contributing to precision medicine, there are still limitations to be overcome before it reaches clinical setting. Hence, the current status of DNA methylation biomarkers was reviewed and the future use in clinic was also predicted.

Berger SL, Kouzarides T, Shiekhattar R, Shilatifard A. An operational definition of epigenetics. Genes Dev. 2009;23(7):781–3. doi:10.1101/gad.1787609.PubMedPubMedCentralCrossRef

Schmidt-Wolf IG, Plass C, Byrd JC, Frevel K, Pietsch T, Waha A. Assessment of promoter methylation identifies PTCH as a putative tumor-suppressor gene in human CLL. Anticancer Res. 2016;36(9):4515–9.PubMedCrossRef

Li L, Li C, Mao H, Du Z, Chan WY, Murray P, et al. Epigenetic inactivation of the CpG demethylase TET1 as a DNA methylation feedback loop in human cancers. Sci Rep. 2016;6:26591. doi:10.1038/srep26591.PubMedPubMedCentralCrossRef

Reis AH, Vargas FR, Lemos B. Biomarkers of genome instability and cancer epigenetics. Tumour Biol. 2016;. doi:10.1007/s13277-016-5278-5.

Deng D, Liu Z, Du Y. Epigenetic alterations as cancer diagnostic, prognostic, and predictive biomarkers. Adv Genet. 2010;71:125–76. doi:10.1016/B978-0-12-380864-6.00005-5.PubMed

Klutstein M, Nejman D, Greenfield R, Cedar H. DNA methylation in cancer and aging. Can Res. 2016;76(12):3446–50. doi:10.1158/0008-5472.CAN-15-3278.CrossRef

Craig JM, Bickmore WA. The distribution of CpG islands in mammalian chromosomes. Nat Genet. 1994;7(3):376–82. doi:10.1038/ng0794-376.PubMedCrossRef

Man CH, Fung TK, Wan H, Cher CY, Fan A, Ng N, et al. Suppression of SOX7 by DNA methylation and its tumor suppressor function in acute myeloid leukemia. Blood. 2015;125(25):3928–36. doi:10.1182/blood-2014-06-580993.PubMedCrossRef

Min HL, Kim J, Kim WH, Jang BG, Kim MA. Epigenetic silencing of the putative tumor suppressor gene GLDC (glycine dehydrogenase) in gastric carcinoma. Anticancer Res. 2016;36(1):179–87.PubMed

10.

Gaudet F, Hodgson JG, Eden A, Jackson-Grusby L, Dausman J, Gray JW, et al. Induction of tumors in mice by genomic hypomethylation. Science. 2003;300(5618):489–92. doi:10.1126/science.1083558.PubMedCrossRef

11.

Kawano H, Saeki H, Kitao H, Tsuda Y, Otsu H, Ando K, et al. Chromosomal instability associated with global DNA hypomethylation is associated with the initiation and progression of esophageal squamous cell carcinoma. Ann Surg Oncol. 2014;21(Suppl 4):S696–702. doi:10.1245/s10434-014-3818-z.PubMedCrossRef

12.

Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3(6):415–28. doi:10.1038/nrg816.PubMedCrossRef

13.

Bird A. DNA methylation patterns and epigenetic memory. Genes Dev. 2002;16(1):6–21. doi:10.1101/gad.947102.PubMedCrossRef

14.

Jia D, Jurkowska RZ, Zhang X, Jeltsch A, Cheng X. Structure of Dnmt3a bound to Dnmt3L suggests a model for de novo DNA methylation. Nature. 2007;449(7159):248–51. doi:10.1038/nature06146.PubMedPubMedCentralCrossRef

15.

Uysal F, Akkoyunlu G, Ozturk S. DNA methyltransferases exhibit dynamic expression during spermatogenesis. Reprod Biomed Online. 2016;33(6):690–702. doi:10.1016/j.rbmo.2016.08.022.PubMedCrossRef

16.

Rodriguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med. 2011;17(3):330–9. doi:10.1038/nm.2305.PubMedCrossRef

17.

Singal R, Wang SZ, Sargent T, Zhu SZ, Ginder GD. Methylation of promoter proximal-transcribed sequences of an embryonic globin gene inhibits transcription in primary erythroid cells and promotes formation of a cell type-specific methyl cytosine binding complex. J Biol Chem. 2002;277(3):1897–905. doi:10.1074/jbc.M105580200.PubMedCrossRef

18.

Kass SU, Pruss D, Wolffe AP. How does DNA methylation repress transcription? Trends Genet TIG. 1997;13(11):444–9.PubMedCrossRef

19.

Ahuja N, Sharma AR, Baylin SB. Epigenetic therapeutics: a new weapon in the war against cancer. Annu Rev Med. 2016;67:73–89. doi:10.1146/annurev-med-111314-035900.PubMedPubMedCentralCrossRef

20.

Tan K, Kajino K, Momose S, Masaoka A, Sasahara K, Shiomi K, et al. Mesothelin (MSLN) promoter is hypomethylated in malignant mesothelioma, but its expression is not associated with methylation status of the promoter. Hum Pathol. 2010;41(9):1330–8. doi:10.1016/j.humpath.2010.03.002.PubMedCrossRef

21.

Daskalos A, Nikolaidis G, Xinarianos G, Savvari P, Cassidy A, Zakopoulou R, et al. Hypomethylation of retrotransposable elements correlates with genomic instability in non-small cell lung cancer. Int J Cancer. 2009;124(1):81–7. doi:10.1002/ijc.23849.PubMedCrossRef

22.

Hama R, Watanabe Y, Shinada K, Yamada Y, Ogata Y, Yoshida Y, et al. Characterization of DNA hypermethylation in two cases of peritoneal mesothelioma. Tumour Biol. 2012;33(6):2031–40. doi:10.1007/s13277-012-0462-8.PubMedCrossRef

23.

Ollikainen M, Smith KR, Joo EJ, Ng HK, Andronikos R, Novakovic B, et al. DNA methylation analysis of multiple tissues from newborn twins reveals both genetic and intrauterine components to variation in the human neonatal epigenome. Hum Mol Genet. 2010;19(21):4176–88. doi:10.1093/hmg/ddq336.PubMedCrossRef

24.

Godfrey KM, Sheppard A, Gluckman PD, Lillycrop KA, Burdge GC, McLean C, et al. Epigenetic gene promoter methylation at birth is associated with child’s later adiposity. Diabetes. 2011;60(5):1528–34. doi:10.2337/db10-0979.PubMedPubMedCentralCrossRef

25.

Lowe R, Rakyan VK. Correcting for cell-type composition bias in epigenome-wide association studies. Genome Med. 2014;6(3):23. doi:10.1186/gm540.PubMedPubMedCentralCrossRef

26.

Montano CM, Irizarry RA, Kaufmann WE, Talbot K, Gur RE, Feinberg AP, et al. Measuring cell-type specific differential methylation in human brain tissue. Genome Biol. 2013;14(8):R94. doi:10.1186/gb-2013-14-8-r94.PubMedPubMedCentralCrossRef

27.

Moverare-Skrtic S, Mellstrom D, Vandenput L, Ehrich M, Ohlsson C. Peripheral blood leukocyte distribution and body mass index are associated with the methylation pattern of the androgen receptor promoter. Endocrine. 2009;35(2):204–10. doi:10.1007/s12020-009-9153-7.PubMedCrossRef

28.

Accomando WP, Wiencke JK, Houseman EA, Nelson HH, Kelsey KT. Quantitative reconstruction of leukocyte subsets using DNA methylation. Genome Biol. 2014;15(3):R50. doi:10.1186/gb-2014-15-3-r50.PubMedPubMedCentralCrossRef

29.

Goltz D, Holmes EE, Gevensleben H, Sailer V, Dietrich J, Jung M, et al. CXCL12 promoter methylation and PD-L1 expression as prognostic biomarkers in prostate cancer patients. Oncotarget. 2016;. doi:10.18632/oncotarget.10786.

30.

Yu M, Carter KT, Makar KW, Vickers K, Ulrich CM, Schoen RE, et al. MethyLight droplet digital PCR for detection and absolute quantification of infrequently methylated alleles. Epigenetics. 2015;10(9):803–9. doi:10.1080/15592294.2015.1068490.PubMedPubMedCentralCrossRef

31.

Lim AM, Candiloro IL, Wong N, Collins M, Do H, Takano EA, et al. Quantitative methodology is critical for assessing DNA methylation and impacts on correlation with patient outcome. Clin Epigenetics. 2014;6(1):22. doi:10.1186/1868-7083-6-22.PubMedPubMedCentralCrossRef

32.

Neri F, Incarnato D, Krepelova A, Parlato C, Oliviero S. Methylation-assisted bisulfite sequencing to simultaneously map 5fC and 5caC on a genome-wide scale for DNA demethylation analysis. Nat Protoc. 2016;11(7):1191–205. doi:10.1038/nprot.2016.063.PubMedCrossRef

33.

Song X, Huang F, Liu J, Li C, Gao S, Wu W, et al. Genome-wide DNA methylomes from discrete developmental stages reveal the predominance of non-CpG methylation in Tribolium castaneum. DNA Res. 2017;. doi:10.1093/dnares/dsx016.PubMedPubMedCentral

34.

Kim KD, El Baidouri M, Jackson SA. Accessing epigenetic variation in the plant methylome. Brief Funct Genom. 2014;13(4):318–27. doi:10.1093/bfgp/elu003.CrossRef

35.

Kim KD, El Baidouri M, Abernathy B, Iwata-Otsubo A, Chavarro C, Gonzales M, et al. A comparative epigenomic analysis of polyploidy-derived genes in soybean and common bean. Plant Physiol. 2015;168(4):1433–47. doi:10.1104/pp.15.00408.PubMedPubMedCentralCrossRef

36.

Murphy PJ, Cairns BR. Genome-wide DNA methylation profiling in zebrafish. Methods Cell Biol. 2016;135:345–59. doi:10.1016/bs.mcb.2016.05.002.PubMedCrossRef

37.

Harris RA, Wang T, Coarfa C, Nagarajan RP, Hong C, Downey SL, et al. Comparison of sequencing-based methods to profile DNA methylation and identification of monoallelic epigenetic modifications. Nat Biotechnol. 2010;28(10):1097–105. doi:10.1038/nbt.1682.PubMedPubMedCentralCrossRef

38.

Rehm HL, Berg JS, Brooks LD, Bustamante CD, Evans JP, Landrum MJ, et al. ClinGen–the clinical genome resource. N Engl J Med. 2015;372(23):2235–42. doi:10.1056/NEJMsr1406261.PubMedPubMedCentralCrossRef

39.

Song L, James SR, Kazim L, Karpf AR. Specific method for the determination of genomic DNA methylation by liquid chromatography-electrospray ionization tandem mass spectrometry. Anal Chem. 2005;77(2):504–10. doi:10.1021/ac0489420.PubMedCrossRef

40.

Kok RM, Smith DE, Barto R, Spijkerman AM, Teerlink T, Gellekink HJ, et al. Global DNA methylation measured by liquid chromatography-tandem mass spectrometry: analytical technique, reference values and determinants in healthy subjects. Clin Chem Lab Med. 2007;45(7):903–11. doi:10.1515/CCLM.2007.137.PubMedCrossRef

41.

Le T, Kim KP, Fan G, Faull KF. A sensitive mass spectrometry method for simultaneous quantification of DNA methylation and hydroxymethylation levels in biological samples. Anal Biochem. 2011;412(2):203–9. doi:10.1016/j.ab.2011.01.026.PubMedPubMedCentralCrossRef

42.

Piyathilake CJ, Johanning GL, Frost AR, Whiteside MA, Manne U, Grizzle WE, et al. Immunohistochemical evaluation of global DNA methylation: comparison with in vitro radiolabeled methyl incorporation assay. Biotech Histochem. 2000;75(6):251–8.PubMedCrossRef

43.

Kremer D, Metzger S, Kolb-Bachofen V, Kremer D. Quantitative measurement of genome-wide DNA methylation by a reliable and cost-efficient enzyme-linked immunosorbent assay technique. Anal Biochem. 2012;422(2):74–8. doi:10.1016/j.ab.2011.11.033.PubMedCrossRef

44.

Li W, Liu M. Distribution of 5-hydroxymethylcytosine in different human tissues. J Nucleic Acids. 2011;2011:870726. doi:10.4061/2011/870726.PubMedPubMedCentralCrossRef

45.

Li M, Chen WD, Papadopoulos N, Goodman SN, Bjerregaard NC, Laurberg S, et al. Sensitive digital quantification of DNA methylation in clinical samples. Nat Biotechnol. 2009;27(9):858–63. doi:10.1038/nbt.1559.PubMedPubMedCentralCrossRef

46.

Iliopoulos D, Guler G, Han SY, Johnston D, Druck T, McCorkell KA, et al. Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer. Oncogene. 2005;24(9):1625–33. doi:10.1038/sj.onc.1208398.PubMedCrossRef

47.

Michels KB, Binder AM, Dedeurwaerder S, Epstein CB, Greally JM, Gut I, et al. Recommendations for the design and analysis of epigenome-wide association studies. Nat Methods. 2013;10(10):949–55. doi:10.1038/nmeth.2632.PubMedCrossRef

48.

Rakyan VK, Down TA, Balding DJ, Beck S. Epigenome-wide association studies for common human diseases. Nat Rev Genet. 2011;12(8):529–41. doi:10.1038/nrg3000.PubMedPubMedCentralCrossRef

49.

Kagan J, Srivastava S, Barker PE, Belinsky SA, Cairns P. Towards clinical application of methylated DNA sequences as cancer biomarkers: a joint NCI’s EDRN and NIST workshop on standards, methods, assays, reagents and tools. Cancer Res. 2007;67(10):4545–9. doi:10.1158/0008-5472.CAN-06-2888.PubMedCrossRef

50.

Riggs AD, Jones PA. 5-Methylcytosine, gene regulation, and cancer. Adv Cancer Res. 1983;40:1–30.PubMedCrossRef

51.

Jin Z, Cheng Y, Gu W, Zheng Y, Sato F, Mori Y, et al. A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett’s esophagus. Can Res. 2009;69(10):4112–5. doi:10.1158/0008-5472.CAN-09-0028.CrossRef

52.

Martinez-Galan J, Torres B, Del Moral R, Munoz-Gamez JA, Martin-Oliva D, Villalobos M, et al. Quantitative detection of methylated ESR1 and 14-3-3-sigma gene promoters in serum as candidate biomarkers for diagnosis of breast cancer and evaluation of treatment efficacy. Cancer Biol Ther. 2008;7(6):958–65.PubMedCrossRef

53.

Li M, Gao F, Xia Y, Tang Y, Zhao W, Jin C, et al. Filtrating colorectal cancer associated genes by integrated analyses of global DNA methylation and hydroxymethylation in cancer and normal tissue. Sci Rep. 2016;6:31826. doi:10.1038/srep31826.PubMedPubMedCentralCrossRef

54.

Li Y, Hu Y, Dong C, Lu H, Zhang C, Hu Q, et al. Vimentin-Mediated Steroidogenesis Induced by Phthalate Esters: involvement of DNA demethylation and nuclear factor kappaB. PLoS ONE. 2016;11(1):e0146138. doi:10.1371/journal.pone.0146138.PubMedPubMedCentralCrossRef

55.

Powrozek T, Krawczyk P, Kucharczyk T, Milanowski J. Septin 9 promoter region methylation in free circulating DNA-potential role in noninvasive diagnosis of lung cancer: preliminary report. Med Oncol. 2014;31(4):917. doi:10.1007/s12032-014-0917-4.PubMedPubMedCentralCrossRef

56.

Oh T, Kim N, Moon Y, Kim MS, Hoehn BD, Park CH, et al. Genome-wide identification and validation of a novel methylation biomarker, SDC2, for blood-based detection of colorectal cancer. J Mol Diagn JMD. 2013;15(4):498–507. doi:10.1016/j.jmoldx.2013.03.004.PubMedCrossRef

57.

Fang C, Wei XM, Zeng XT, Wang FB, Weng H, Long X. Aberrant GSTP1 promoter methylation is associated with increased risk and advanced stage of breast cancer: a meta-analysis of 19 case-control studies. BMC Cancer. 2015;15:920. doi:10.1186/s12885-015-1926-1.PubMedPubMedCentralCrossRef

58.

Wijetunga NA, Belbin TJ, Burk RD, Whitney K, Abadi M, Greally JM, et al. Novel epigenetic changes in CDKN2A are associated with progression of cervical intraepithelial neoplasia. Gynecol Oncol. 2016;. doi:10.1016/j.ygyno.2016.07.006.PubMedPubMedCentral

59.

Jung M, Putzer S, Gevensleben H, Meller S, Kristiansen G, Dietrich D. Diagnostic and prognostic value of SHOX2 and SEPT9 DNA methylation and cytology in benign, paramalignant, and malignant ascites. Clin Epigenetics. 2016;8:24. doi:10.1186/s13148-016-0192-7.PubMedPubMedCentralCrossRef

60.

Darwiche K, Zarogoulidis P, Baehner K, Welter S, Tetzner R, Wohlschlaeger J, et al. Assessment of SHOX2 methylation in EBUS-TBNA specimen improves accuracy in lung cancer staging. Ann Oncol. 2013;24(11):2866–70. doi:10.1093/annonc/mdt365.PubMedCrossRef

61.

Dietrich D, Hasinger O, Liebenberg V, Field JK, Kristiansen G, Soltermann A. DNA methylation of the homeobox genes PITX2 and SHOX2 predicts outcome in non-small-cell lung cancer patients. Diagn Mol Pathol. 2012;21(2):93–104. doi:10.1097/PDM.0b013e318240503b.PubMedCrossRef

62.

Dietrich D, Jung M, Puetzer S, Leisse A, Holmes EE, Meller S, et al. Diagnostic and prognostic value of SHOX2 and SEPT9 DNA methylation and cytology in benign, paramalignant and malignant pleural effusions. PLoS ONE. 2013;8(12):e84225. doi:10.1371/journal.pone.0084225.PubMedPubMedCentralCrossRef

63.

Payne SR. From discovery to the clinic: the novel DNA methylation biomarker (m)SEPT9 for the detection of colorectal cancer in blood. Epigenomics. 2010;2(4):575–85. doi:10.2217/epi.10.35.PubMedCrossRef

64.

Wick W, Weller M, van den Bent M, Sanson M, Weiler M, von Deimling A, et al. MGMT testing–the challenges for biomarker-based glioma treatment. Nat Rev Neurol. 2014;10(7):372–85. doi:10.1038/nrneurol.2014.100.PubMedCrossRef

65.

Yin AA, Zhang LH, Cheng JX, Dong Y, Liu BL, Han N, et al. The predictive but not prognostic value of MGMT promoter methylation status in elderly glioblastoma patients: a meta-analysis. PLoS ONE. 2014;9(1):e85102. doi:10.1371/journal.pone.0085102.PubMedPubMedCentralCrossRef

66.

Zhang K, Wang XQ, Zhou B, Zhang L. The prognostic value of MGMT promoter methylation in Glioblastoma multiforme: a meta-analysis. Fam Cancer. 2013;12(3):449–58. doi:10.1007/s10689-013-9607-1.PubMedCrossRef

67.

Chen Y, Li J, Yu X, Li S, Zhang X, Mo Z, et al. APC gene hypermethylation and prostate cancer: a systematic review and meta-analysis. Eur J Hum Genet EJHG. 2013;21(9):929–35. doi:10.1038/ejhg.2012.281.PubMedCrossRef

68.

Wu T, Giovannucci E, Welge J, Mallick P, Tang WY, Ho SM. Measurement of GSTP1 promoter methylation in body fluids may complement PSA screening: a meta-analysis. Br J Cancer. 2011;105(1):65–73. doi:10.1038/bjc.2011.143.PubMedPubMedCentralCrossRef

69.

Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370(14):1287–97. doi:10.1056/NEJMoa1311194.PubMedCrossRef

70.

Melotte V, Lentjes MH, van den Bosch SM, Hellebrekers DM, de Hoon JP, Wouters KA, et al. N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer. J Natl Cancer Inst. 2009;101(13):916–27. doi:10.1093/jnci/djp131.PubMedCrossRef

71.

Loh K, Chia JA, Greco S, Cozzi SJ, Buttenshaw RL, Bond CE, et al. Bone morphogenic protein 3 inactivation is an early and frequent event in colorectal cancer development. Genes Chromosomes Cancer. 2008;47(6):449–60. doi:10.1002/gcc.20552.PubMedCrossRef

72.

Chen WD, Han ZJ, Skoletsky J, Olson J, Sah J, Myeroff L, et al. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst. 2005;97(15):1124–32. doi:10.1093/jnci/dji204.PubMedCrossRef

73.

Semaan A, van Ellen A, Meller S, Bergheim D, Branchi V, Lingohr P, et al. SEPT9 and SHOX2 DNA methylation status and its utility in the diagnosis of colonic adenomas and colorectal adenocarcinomas. Clin Epigenetics. 2016;8:100. doi:10.1186/s13148-016-0267-5.PubMedPubMedCentralCrossRef

74.

Gonzalez ME, Peterson EA, Privette LM, Loffreda-Wren JL, Kalikin LM, Petty EM. High SEPT9_v1 expression in human breast cancer cells is associated with oncogenic phenotypes. Can Res. 2007;67(18):8554–64. doi:10.1158/0008-5472.CAN-07-1474.CrossRef

75.

Connolly D, Yang Z, Castaldi M, Simmons N, Oktay MH, Coniglio S, et al. Septin 9 isoform expression, localization and epigenetic changes during human and mouse breast cancer progression. Breast Cancer Res BCR. 2011;13(4):R76. doi:10.1186/bcr2924.PubMedCrossRef

76.

Hrasovec S, Hauptman N, Glavac D, Jelenc F, Ravnik-Glavac M. TMEM25 is a candidate biomarker methylated and down-regulated in colorectal cancer. Dis Markers. 2013;34(2):93–104. doi:10.3233/DMA-120948.PubMedPubMedCentralCrossRef

77.

Li JZ, Zhang Y, Wen B, Li M, Wang YJ. Ability of PITX2 methylation to predict survival in patients with prostate cancer. OncoTargets Therapy. 2015;8:3507–12. doi:10.2147/OTT.S83914.PubMedPubMedCentral

78.

Litovkin K, Joniau S, Lerut E, Laenen A, Gevaert O, Spahn M, et al. Methylation of PITX2, HOXD3, RASSF1 and TDRD1 predicts biochemical recurrence in high-risk prostate cancer. J Cancer Res Clin Oncol. 2014;140(11):1849–61. doi:10.1007/s00432-014-1738-8.PubMedCrossRef

79.

Kneip C, Schmidt B, Seegebarth A, Weickmann S, Fleischhacker M, Liebenberg V, et al. SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer in plasma. J Thorac Oncol. 2011;6(10):1632–8. doi:10.1097/JTO.0b013e318220ef9a.PubMedCrossRef

80.

Schmidt B, Liebenberg V, Dietrich D, Schlegel T, Kneip C, Seegebarth A, et al. SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer based on bronchial aspirates. BMC Cancer. 2010;10:600. doi:10.1186/1471-2407-10-600.PubMedPubMedCentralCrossRef

81.

Ilse P, Biesterfeld S, Pomjanski N, Fink C, Schramm M. SHOX2 DNA methylation is a tumour marker in pleural effusions. Cancer Genomics Proteomics. 2013;10(5):217–23.PubMed

82.

Kaina B, Christmann M, Naumann S, Roos WP. MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair. 2007;6(8):1079–99. doi:10.1016/j.dnarep.2007.03.008.PubMedCrossRef

83.

Chen YP, Hou XY, Yang CS, Jiang XX, Yang M, Xu XF, et al. DNA methylation and histone acetylation regulate the expression of MGMT and chemosensitivity to temozolomide in malignant melanoma cell lines. Tumour Biol. 2016;. doi:10.1007/s13277-016-4994-1.

84.

Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997–1003. doi:10.1056/NEJMoa043331.PubMedCrossRef

85.

Wang W, Zhang L, Wang Z, Yang F, Wang H, Liang T, et al. A three-gene signature for prognosis in patients with MGMT promoter-methylated glioblastoma. Oncotarget. 2016;. doi:10.18632/oncotarget.11726.

86.

Cros J, Hentic O, Rebours V, Zappa M, Gille N, Theou-Anton N, et al. MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2016;23(8):625–33. doi:10.1530/ERC-16-0117.PubMedCrossRef

87.

Dunn J, Baborie A, Alam F, Joyce K, Moxham M, Sibson R, et al. Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Br J Cancer. 2009;101(1):124–31. doi:10.1038/sj.bjc.6605127.PubMedPubMedCentralCrossRef

88.

Reifenberger G, Hentschel B, Felsberg J, Schackert G, Simon M, Schnell O, et al. Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. Int J Cancer. 2012;131(6):1342–50. doi:10.1002/ijc.27385.PubMedCrossRef

89.

van den Bent MJ, Dubbink HJ, Sanson M, van der Lee-Haarloo CR, Hegi M, Jeuken JW, et al. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. J Clin Oncol. 2009;27(35):5881–6. doi:10.1200/JCO.2009.24.1034.PubMedPubMedCentralCrossRef

90.

Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006;38(7):787–93. doi:10.1038/ng1834.PubMedCrossRef

91.

Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet TIG. 2000;16(4):168–74.PubMedCrossRef

92.

van der Velden PA, Metzelaar-Blok JA, Bergman W, Monique H, Hurks H, Frants RR, et al. Promoter hypermethylation: a common cause of reduced p16(INK4a) expression in uveal melanoma. Can Res. 2001;61(13):5303–6.

93.

Pfeifer GP, Yoon JH, Liu L, Tommasi S, Wilczynski SP, Dammann R. Methylation of the RASSF1A gene in human cancers. Biol Chem. 2002;383(6):907–14. doi:10.1515/BC.2002.097.PubMedCrossRef

94.

Shivakumar L, Minna J, Sakamaki T, Pestell R, White MA. The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation. Mol Cell Biol. 2002;22(12):4309–18.PubMedPubMedCentralCrossRef

95.

Calipel A, Abonnet V, Nicole O, Mascarelli F, Coupland SE, Damato B, et al. Status of RASSF1A in uveal melanocytes and melanoma cells. Mol Cancer Res MCR. 2011;9(9):1187–98. doi:10.1158/1541-7786.MCR-10-0437.PubMedCrossRef

96.

Maat W, van der Velden PA, Out-Luiting C, Plug M, Dirks-Mulder A, Jager MJ, et al. Epigenetic inactivation of RASSF1a in uveal melanoma. Invest Ophthalmol Vis Sci. 2007;48(2):486–90. doi:10.1167/iovs.06-0781.PubMedCrossRef

97.

Venza M, Visalli M, Catalano T, Beninati C, Teti D, Venza I. DSS1 promoter hypomethylation and overexpression predict poor prognosis in melanoma and squamous cell carcinoma patients. Hum Pathol. 2017;60:137–46. doi:10.1016/j.humpath.2016.10.018.PubMedCrossRef

98.

Li FJ, Li LM, Zhang RH, Xu C, Zhou P, Long J, et al. The role of 5-hydroxymethylcytosine in melanoma. Melanoma Res. 2017;27(3):175–9. doi:10.1097/CMR.0000000000000349.PubMedCrossRef

99.

Wu X, Zhang Y. TET-mediated active DNA demethylation: mechanism, function and beyond. Nat Rev Genet. 2017;. doi:10.1038/nrg.2017.33.PubMed

100.

Lorsbach RB, Moore J, Mathew S, Raimondi SC, Mukatira ST, Downing JR. TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23). Leukemia. 2003;17(3):637–41. doi:10.1038/sj.leu.2402834.PubMedCrossRef

101.

Huang H, Jiang X, Li Z, Li Y, Song CX, He C, et al. TET1 plays an essential oncogenic role in MLL-rearranged leukemia. Proc Natl Acad Sci USA. 2013;110(29):11994–9. doi:10.1073/pnas.1310656110.PubMedPubMedCentralCrossRef

102.

Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M, et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet. 2009;41(7):838–42. doi:10.1038/ng.391.PubMedCrossRef

103.

Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Masse A, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009;360(22):2289–301. doi:10.1056/NEJMoa0810069.PubMedCrossRef

104.

Wang Y, Xiao M, Chen X, Chen L, Xu Y, Lv L, et al. WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferation. Mol Cell. 2015;57(4):662–73. doi:10.1016/j.molcel.2014.12.023.PubMedPubMedCentralCrossRef

105.

Wu MZ, Chen SF, Nieh S, Benner C, Ger LP, Jan CI, et al. Hypoxia drives breast tumor malignancy through a TET-TNFalpha-p38-MAPK signaling axis. Can Res. 2015;75(18):3912–24. doi:10.1158/0008-5472.CAN-14-3208.CrossRef

106.

Yang H, Liu Y, Bai F, Zhang JY, Ma SH, Liu J, et al. Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Oncogene. 2013;32(5):663–9. doi:10.1038/onc.2012.67.PubMedCrossRef

107.

Hsu CH, Peng KL, Kang ML, Chen YR, Yang YC, Tsai CH, et al. TET1 suppresses cancer invasion by activating the tissue inhibitors of metalloproteinases. Cell Rep. 2012;2(3):568–79. doi:10.1016/j.celrep.2012.08.030.PubMedCrossRef

108.

Liu C, Liu L, Chen X, Shen J, Shan J, Xu Y, et al. Decrease of 5-hydroxymethylcytosine is associated with progression of hepatocellular carcinoma through downregulation of TET1. PLoS ONE. 2013;8(5):e62828. doi:10.1371/journal.pone.0062828.PubMedPubMedCentralCrossRef

109.

Muller T, Gessi M, Waha A, Isselstein LJ, Luxen D, Freihoff D, et al. Nuclear exclusion of TET1 is associated with loss of 5-hydroxymethylcytosine in IDH1 wild-type gliomas. Am J Pathol. 2012;181(2):675–83. doi:10.1016/j.ajpath.2012.04.017.PubMedCrossRef

110.

Orr BA, Haffner MC, Nelson WG, Yegnasubramanian S, Eberhart CG. Decreased 5-hydroxymethylcytosine is associated with neural progenitor phenotype in normal brain and shorter survival in malignant glioma. PLoS ONE. 2012;7(7):e41036. doi:10.1371/journal.pone.0041036.PubMedPubMedCentralCrossRef

111.

Lian CG, Xu Y, Ceol C, Wu F, Larson A, Dresser K, et al. Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell. 2012;150(6):1135–46. doi:10.1016/j.cell.2012.07.033.PubMedPubMedCentralCrossRef

112.

Kudo Y, Tateishi K, Yamamoto K, Yamamoto S, Asaoka Y, Ijichi H, et al. Loss of 5-hydroxymethylcytosine is accompanied with malignant cellular transformation. Cancer Sci. 2012;103(4):670–6. doi:10.1111/j.1349-7006.2012.02213.x.PubMedCrossRef

113.

Rawluszko-Wieczorek AA, Siera A, Horbacka K, Horst N, Krokowicz P, Jagodzinski PP. Clinical significance of DNA methylation mRNA levels of TET family members in colorectal cancer. J Cancer Res Clin Oncol. 2015;141(8):1379–92. doi:10.1007/s00432-014-1901-2.PubMedPubMedCentralCrossRef

114.

Frycz BA, Murawa D, Borejsza-Wysocki M, Marciniak R, Murawa P, Drews M, et al. Decreased expression of ten-eleven translocation 1 protein is associated with some clinicopathological features in gastric cancer. Biomed Pharmacother. 2014;68(2):209–12. doi:10.1016/j.biopha.2013.12.011.PubMedCrossRef

115.

Bai J, Zhang X, Hu K, Liu B, Wang H, Li A, et al. Silencing DNA methyltransferase 1 (DNMT1) inhibits proliferation, metastasis and invasion in ESCC by suppressing methylation of RASSF1A and DAPK. Oncotarget. 2016;. doi:10.18632/oncotarget.9866.

116.

El-Deiry WS, Nelkin BD, Celano P, Yen RW, Falco JP, Hamilton SR, et al. High expression of the DNA methyltransferase gene characterizes human neoplastic cells and progression stages of colon cancer. Proc Natl Acad Sci USA. 1991;88(8):3470–4.PubMedPubMedCentralCrossRef

117.

Patra SK, Patra A, Zhao H, Dahiya R. DNA methyltransferase and demethylase in human prostate cancer. Mol Carcinog. 2002;33(3):163–71.PubMedCrossRef

118.

Girault I, Tozlu S, Lidereau R, Bieche I. Expression analysis of DNA methyltransferases 1, 3A, and 3B in sporadic breast carcinomas. Clin Cancer Res. 2003;9(12):4415–22.PubMed

119.

Girault I, Lerebours F, Amarir S, Tozlu S, Tubiana-Hulin M, Lidereau R, et al. Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen. Clin Cancer Res. 2003;9(4):1259–66.PubMed

120.

Oh BK, Kim H, Park HJ, Shim YH, Choi J, Park C, et al. DNA methyltransferase expression and DNA methylation in human hepatocellular carcinoma and their clinicopathological correlation. Int J Mol Med. 2007;20(1):65–73.PubMed

121.

Melki JR, Warnecke P, Vincent PC, Clark SJ. Increased DNA methyltransferase expression in leukaemia. Leukemia. 1998;12(3):311–6.PubMedCrossRef

122.

Yang L, Rodriguez B, Mayle A, Park HJ, Lin X, Luo M, et al. DNMT3A loss drives enhancer hypomethylation in FLT3-ITD-associated leukemias. Cancer Cell. 2016;29(6):922–34. doi:10.1016/j.ccell.2016.05.003.PubMedPubMedCentralCrossRef

123.

Peters SL, Hlady RA, Opavska J, Klinkebiel D, Pirruccello SJ, Talmon GA, et al. Tumor suppressor functions of Dnmt3a and Dnmt3b in the prevention of malignant mouse lymphopoiesis. Leukemia. 2014;28(5):1138–42. doi:10.1038/leu.2013.364.PubMedCrossRef

124.

Klein CJ, Botuyan MV, Wu Y, Ward CJ, Nicholson GA, Hammans S, et al. Mutations in DNMT1 cause hereditary sensory neuropathy with dementia and hearing loss. Nat Genet. 2011;43(6):595–600. doi:10.1038/ng.830.PubMedPubMedCentralCrossRef

125.

Winkelmann J, Lin L, Schormair B, Kornum BR, Faraco J, Plazzi G, et al. Mutations in DNMT1 cause autosomal dominant cerebellar ataxia, deafness and narcolepsy. Hum Mol Genet. 2012;21(10):2205–10. doi:10.1093/hmg/dds035.PubMedPubMedCentralCrossRef

126.

Mastroeni D, Chouliaras L, Grover A, Liang WS, Hauns K, Rogers J, et al. Reduced RAN expression and disrupted transport between cytoplasm and nucleus; a key event in Alzheimer’s disease pathophysiology. PLoS ONE. 2013;8(1):e53349. doi:10.1371/journal.pone.0053349.PubMedPubMedCentralCrossRef

127.

Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363(25):2424–33. doi:10.1056/NEJMoa1005143.PubMedPubMedCentralCrossRef

128.

Yan XJ, Xu J, Gu ZH, Pan CM, Lu G, Shen Y, et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet. 2011;43(4):309–15. doi:10.1038/ng.788.PubMedCrossRef

129.

Im AP, Sehgal AR, Carroll MP, Smith BD, Tefferi A, Johnson DE, et al. DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. Leukemia. 2014;28(9):1774–83. doi:10.1038/leu.2014.124.PubMedPubMedCentralCrossRef

130.

Figueroa ME, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos PJ, et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell. 2010;17(1):13–27. doi:10.1016/j.ccr.2009.11.020.PubMedPubMedCentralCrossRef

131.

Challen GA, Sun D, Jeong M, Luo M, Jelinek J, Berg JS, et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet. 2011;44(1):23–31. doi:10.1038/ng.1009.PubMedPubMedCentralCrossRef

132.

Xu P, Hu G, Luo C, Liang Z. DNA methyltransferase inhibitors: an updated patent review. Exp Opin Ther Pat. 2016;. doi:10.1080/13543776.2016.1209488.

133.

Khan C, Pathe N, Fazal S, Lister J, Rossetti JM. Azacitidine in the management of patients with myelodysplastic syndromes. Ther Adv Hematol. 2012;3(6):355–73. doi:10.1177/2040620712464882.PubMedPubMedCentralCrossRef

134.

Aimiuwu J, Wang H, Chen P, Xie Z, Wang J, Liu S, et al. RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia. Blood. 2012;119(22):5229–38. doi:10.1182/blood-2011-11-382226.PubMedPubMedCentralCrossRef

135.

Cheng JC, Matsen CB, Gonzales FA, Ye W, Greer S, Marquez VE, et al. Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst. 2003;95(5):399–409.PubMedCrossRef

136.

Khan H, Vale C, Bhagat T, Verma A. Role of DNA methylation in the pathogenesis and treatment of myelodysplastic syndromes. Semin Hematol. 2013;50(1):16–37. doi:10.1053/j.seminhematol.2013.01.001.PubMedCrossRef

137.

Kaminskas E, Farrell AT, Wang YC, Sridhara R, Pazdur R. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist. 2005;10(3):176–82. doi:10.1634/theoncologist.10-3-176.PubMedCrossRef

138.

Guo D, Myrdal PB, Karlage KL, O’Connell SP, Wissinger TJ, Tabibi SE, et al. Stability of 5-fluoro-2′-deoxycytidine and tetrahydrouridine in combination. AAPS PharmSciTech. 2010;11(1):247–52. doi:10.1208/s12249-010-9383-2.PubMedPubMedCentralCrossRef

139.

Cheng JC, Yoo CB, Weisenberger DJ, Chuang J, Wozniak C, Liang G, et al. Preferential response of cancer cells to zebularine. Cancer Cell. 2004;6(2):151–8. doi:10.1016/j.ccr.2004.06.023.PubMedCrossRef

140.

Gore SD, Jones C, Kirkpatrick P. Decitabine. Nat Rev Drug Discov. 2006;5(11):891–2. doi:10.1038/nrd2180.PubMedCrossRef

141.

Coronel J, Cetina L, Pacheco I, Trejo-Becerril C, Gonzalez-Fierro A, de la Cruz-Hernandez E, et al. A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results. Med Oncol. 2011;28(Suppl 1):S540–6. doi:10.1007/s12032-010-9700-3.PubMedCrossRef

142.

Lee BH, Yegnasubramanian S, Lin X, Nelson WG. Procainamide is a specific inhibitor of DNA methyltransferase 1. J Biol Chem. 2005;280(49):40749–56. doi:10.1074/jbc.M505593200.PubMedPubMedCentralCrossRef

143.

Yang X, Lay F, Han H, Jones PA. Targeting DNA methylation for epigenetic therapy. Trends Pharmacol Sci. 2010;31(11):536–46. doi:10.1016/j.tips.2010.08.001.PubMedPubMedCentralCrossRef

144.

Datta J, Ghoshal K, Denny WA, Gamage SA, Brooke DG, Phiasivongsa P, et al. A new class of quinoline-based DNA hypomethylating agents reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradation. Can Res. 2009;69(10):4277–85. doi:10.1158/0008-5472.CAN-08-3669.CrossRef

145.

Nandakumar V, Vaid M, Katiyar SK. (–)-Epigallocatechin-3-gallate reactivates silenced tumor suppressor genes, Cip1/p21 and p16INK4a, by reducing DNA methylation and increasing histones acetylation in human skin cancer cells. Carcinogenesis. 2011;32(4):537–44. doi:10.1093/carcin/bgq285.PubMedPubMedCentralCrossRef

146.

Stresemann C, Brueckner B, Musch T, Stopper H, Lyko F. Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. Can Res. 2006;66(5):2794–800. doi:10.1158/0008-5472.CAN-05-2821.CrossRef

147.

Garzon R, Liu S, Fabbri M, Liu Z, Heaphy CE, Callegari E, et al. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood. 2009;113(25):6411–8. doi:10.1182/blood-2008-07-170589.PubMedPubMedCentralCrossRef

148.

Song SH, Han SW, Bang YJ. Epigenetic-based therapies in cancer: progress to date. Drugs. 2011;71(18):2391–403. doi:10.2165/11596690-000000000-00000.PubMedCrossRef

149.

Valente S, Liu Y, Schnekenburger M, Zwergel C, Cosconati S, Gros C, et al. Selective non-nucleoside inhibitors of human DNA methyltransferases active in cancer including in cancer stem cells. J Med Chem. 2014;57(3):701–13. doi:10.1021/jm4012627.PubMedPubMedCentralCrossRef

150.

Gros C, Fleury L, Nahoum V, Faux C, Valente S, Labella D, et al. New insights on the mechanism of quinoline-based DNA Methyltransferase inhibitors. J Biol Chem. 2015;290(10):6293–302. doi:10.1074/jbc.M114.594671.PubMedCrossRef

151.

Rilova E, Erdmann A, Gros C, Masson V, Aussagues Y, Poughon-Cassabois V, et al. Design, synthesis and biological evaluation of 4-amino-N-(4-aminophenyl)benzamide analogues of quinoline-based SGI-1027 as inhibitors of DNA methylation. ChemMedChem. 2014;9(3):590–601. doi:10.1002/cmdc.201300420.PubMedPubMedCentralCrossRef

152.

Zielske SP. Epigenetic DNA methylation in radiation biology: on the field or on the sidelines? J Cell Biochem. 2015;116(2):212–7. doi:10.1002/jcb.24959.PubMedCrossRef

153.

Gnyszka A, Jastrzebski Z, Flis S. DNA methyltransferase inhibitors and their emerging role in epigenetic therapy of cancer. Anticancer Res. 2013;33(8):2989–96.PubMed

154.

Das DS, Ray A, Das A, Song Y, Tian Z, Oronsky B, et al. A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells. Leukemia. 2016;. doi:10.1038/leu.2016.96.

155.

Li Y, Geng P, Jiang W, Wang Y, Yao J, Lin X, et al. Enhancement of radiosensitivity by 5-Aza-CdR through activation of G2/M checkpoint response and apoptosis in osteosarcoma cells. Tumour Biol. 2014;35(5):4831–9. doi:10.1007/s13277-014-1634-5.PubMedCrossRef

156.

Kim JS, Kim SY, Lee M, Kim SH, Kim SM, Kim EJ. Radioresistance in a human laryngeal squamous cell carcinoma cell line is associated with DNA methylation changes and topoisomerase II alpha. Cancer Biol Ther. 2015;16(4):558–66. doi:10.1080/15384047.2015.1017154.PubMedPubMedCentralCrossRef

157.

De Schutter H, Kimpe M, Isebaert S, Nuyts S. A systematic assessment of radiation dose enhancement by 5-Aza-2′-deoxycytidine and histone deacetylase inhibitors in head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2009;73(3):904–12. doi:10.1016/j.ijrobp.2008.10.032.PubMedCrossRef

158.

Kim HJ, Kim JH, Chie EK, Young PD, Kim IA, Kim IH. DNMT (DNA methyltransferase) inhibitors radiosensitize human cancer cells by suppressing DNA repair activity. Radiat Oncol. 2012;7:39. doi:10.1186/1748-717X-7-39.PubMedPubMedCentralCrossRef

159.

Chan AT, Tao Q, Robertson KD, Flinn IW, Mann RB, Klencke B, et al. Azacitidine induces demethylation of the Epstein-Barr virus genome in tumors. J Clin Oncol. 2004;22(8):1373–81. doi:10.1200/JCO.2004.04.185.PubMedCrossRef

160.

Gravina GL, Festuccia C, Marampon F, Popov VM, Pestell RG, Zani BM, et al. Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation. Mol Cancer. 2010;9:305. doi:10.1186/1476-4598-9-305.PubMedPubMedCentralCrossRef

Titel: DNA methylation profiles in cancer diagnosis and therapeutics
verfasst von: Yunbao Pan
Guohong Liu
Fuling Zhou
Bojin Su
Yirong Li
Publikationsdatum: 27.07.2017
Verlag: Springer International Publishing
Erschienen in: Clinical and Experimental Medicine / Ausgabe 1/2018
Print ISSN: 1591-8890
Elektronische ISSN: 1591-9528
DOI: https://doi.org/10.1007/s10238-017-0467-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

DNA methylation profiles in cancer diagnosis and therapeutics

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

Nonassociation of homocysteine gene polymorphisms with treatment outcome in South Indian Tamil Rheumatoid Arthritis patients

Assessing liver proteins and enzymes of medical workers exposed to ionizing radiation (IR)

Detection of promoter methylation status of suppressor of cytokine signaling 3 (SOCS3) in tissue and plasma from Chinese patients with different hepatic diseases

Globulin–platelet model predicts significant fibrosis and cirrhosis in CHB patients with high HBV DNA and mildly elevated alanine transaminase levels

SATB2 suppresses non-small cell lung cancer invasiveness by G9a

Telomere length in the gastric mucosa after Helicobacter pylori eradication and its potential role in the gastric carcinogenesis

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin